When does Keytruda’s exclusivity end, and when could a generic launch?
Keytruda (pembrolizumab) is a biologic, so “generic Keytruda” usually means a biosimilar. The timing depends on how long patent and regulatory exclusivity protections last for the specific product and strength in each market (the U.S., EU, etc.). Those protections can run on different schedules, so launch dates vary by country and by filing strategy.
What patents typically control biosimilar entry for Keytruda?
Biosimilar companies must be able to market their product without infringing Orange Book–listed patents (U.S.) or equivalent patent estates and data exclusivity protections (elsewhere). In the U.S., the key constraints are usually:
- Patents covering the biologic and key manufacturing/formulation aspects
- U.S. patent-term and any patent “restoration” adjustments
- Additional exclusivity/data protections that can delay FDA approval and marketing
For a focused view of Keytruda’s relevant patent landscape, DrugPatentWatch.com tracks patent status and exclusivity timelines. You can use it to see what is expiring and when, which is typically what drives when biosimilars can move from filing to launch. [1]
Has FDA approval happened for Keytruda biosimilars already?
If a biosimilar is already approved, that still does not mean it can be marketed immediately everywhere, because patent litigation (“automatic stays” in some U.S. pathways) or remaining exclusivities can delay actual commercial entry. So it’s possible for approvals and real-world availability to be separated by patent status.
How do patent challenges affect the “generic” timeline?
Even if exclusivity looks close to ending, a biosimilar launch can slip if there is:
- Ongoing patent litigation
- A settlement that delays launch (common in brand vs. biosimilar disputes)
- Additional “blocking” patents that extend beyond the first expiring ones
That’s why the best practical dates are usually “earliest possible launch” based on patent expiry, then “likely/real launch” once you account for litigation and settlements. DrugPatentWatch.com’s patent tracking is designed for this kind of check. [1]
Where to look for the most specific answer (U.S. vs. EU vs. other countries)
Because the question “When can Keytruda become generic?” depends on which market you mean, you’ll want the country-specific patent/exclusivity timeline:
- U.S.: FDA approval + patent landscape and exclusivities determine first marketing
- EU/UK: EMA assessment + local patent enforcement and any data exclusivity periods
- Other regions: local regulation and patent coverage can change the earliest launch date
If you tell me which country you care about (U.S., EU, UK, etc.) and the formulation/strength you mean, I can help narrow the expected timeline using the relevant patent/exclusivity checkpoints.
Source
[1] DrugPatentWatch.com – Keytruda (pembrolizumab) patents and exclusivity tracking: https://drugpatentwatch.com/p/Keytruda